Hepatocyte nuclear factor-4α reverses malignancy of hepatocellular carcinoma through regulating miR-134 in the DLK1-DIO3 region

Hepatology ◽  
2013 ◽  
Vol 58 (6) ◽  
pp. 1964-1976 ◽  
Author(s):  
Chuan Yin ◽  
Pei-Qin Wang ◽  
Wen-Ping Xu ◽  
Yuan Yang ◽  
Qing Zhang ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Nuclear Factor ◽  
Hepatocyte Nuclear Factor ◽  
Hepatocyte Nuclear Factor 4Α

scholarly journals Hepatocyte Nuclear Factor 4α Suppresses the Development of Hepatocellular Carcinoma

2010 ◽  
Vol 70 (19) ◽  
pp. 7640-7651 ◽  
Author(s):  
Bei-Fang Ning ◽  
Jin Ding ◽  
Chuan Yin ◽  
Wei Zhong ◽  
Kun Wu ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Nuclear Factor ◽  
Hepatocyte Nuclear Factor ◽  
Hepatocyte Nuclear Factor 4Α

scholarly journals Apoptosis signal-regulating kinase 1 mediates the inhibitory effect of hepatocyte nuclear factor-4α on hepatocellular carcinoma

Oncotarget ◽  
2016 ◽  
Vol 7 (19) ◽  
pp. 27408-27421 ◽  
Author(s):  
Cai-Feng Jiang ◽  
Liang-Zhi Wen ◽  
Chuan Yin ◽  
Wen-Ping Xu ◽  
Bin Shi ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Inhibitory Effect ◽  
Nuclear Factor ◽  
Hepatocyte Nuclear Factor ◽  
Hepatocyte Nuclear Factor 4Α

scholarly journals Prolyl-4-Hydroxylase 2 Potentially Contributes to Hepatocellular Carcinoma-Associated Erythrocytosis by Maintaining Hepatocyte Nuclear Factor-4α Expression

2015 ◽  
Vol 37 (6) ◽  
pp. 2257-2264
Author(s):  
Wenwen Sun ◽  
Friederike Katharina Kosyna ◽  
Wolfgang Jelkmann ◽  
Reinhard Depping
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hypoxia Inducible Factor ◽  
Significant Risk ◽  
Significant Risk Factor ◽  
Selective Inhibition ◽  
Nuclear Factor ◽  
Hepatocyte Nuclear Factor ◽  
Α Subunit ◽  
Hepatocyte Nuclear Factor 4Α ◽  
Hcc Cells

Background: Increased red blood cell count (Erythrocytosis) is an important paraneoplastic syndrome of hepatocellular carcinoma (HCC) and is a significant risk factor for lethal lung artery thromboembolism. HCC-associated erythrocytosis is partially caused by the ability of several HCC cells to produce erythropoietin (EPO). Prolyl-4-hydroxylase 2 (PHD2) is an enzyme encoded by the gene EGLN1. The best-known function of PHD2 is to mediate the oxygen-dependent degradation of the labile α-subunit of hypoxia-inducible factor (HIF). However, there is increasing evidence that PHD2 also regulates HIF-independent pathways by interacting with other substrates. Methods: In the EPO-producing human HCC cell line HepG2, the expression of PHD2 gene was silenced with siRNA. EPO production was estimated using quantitative PCR and ELISA. Results: In HepG2 cells, PHD2 suppresses the activity of TGF-β1 pathway and consequently maintains the expression of hepatocyte nuclear factor-4α (HNF-4α), an important transcription factor promoting the EPO expression in hepatocytes. PHD2 knockdown caused a marked reduction of EPO production. HIF seemed not to be involved in this biology. Conclusion: Our findings show that PHD2 represents a potential contributing factor for HCC-associated erythrocytosis. Selective inhibition of PHD2 in HCC cells might be considered as a new way to manage erythrocytosis in HCC patients.

scholarly journals Differentiation therapy of hepatocellular carcinoma in mice with recombinant adenovirus carrying hepatocyte nuclear factor-4α gene

Hepatology ◽  
2008 ◽  
Vol 48 (5) ◽  
pp. 1528-1539 ◽  
Author(s):  
Chuan Yin ◽  
Yong Lin ◽  
Xin Zhang ◽  
Yue-Xiang Chen ◽  
Xin Zeng ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Recombinant Adenovirus ◽  
Nuclear Factor ◽  
Hepatocyte Nuclear Factor ◽  
Differentiation Therapy ◽  
Hepatocyte Nuclear Factor 4Α
Sign in / Sign up

Export Citation Format

Share Document